TVRD Stock Chart & Stats
Currently, no data available
Please return soon. This page is being updated.
Bulls Say, Bears Say
Bulls Say
Validated Target Engagement (Phase 1 TTI-109)Phase 1 pharmacodynamic signals demonstrating up to ~60% reductions in STAT3-driven immune cells provide mechanistic validation of TTI-109. This de-risks early development, supports biological plausibility across indications, and strengthens the case for progressing to patient studies and partnerships.
Improved GI Tolerability Vs Prior CompoundA materially improved GI safety profile versus the predecessor enhances long-term clinical viability for chronic indications like ulcerative colitis. Better tolerability can improve retention in trials, broaden patient eligibility, and create a sustainable clinical differentiator versus parenteral biologics.
Clear Strategic Indication Choice: Ulcerative ColitisChoosing ulcerative colitis focuses development on a large, underserved market with unmet needs for oral therapies. This strategic clarity concentrates R&D resources, improves KOL engagement and makes the program more attractive for partnerships or targeted licensing over the next 2–6 months.
Bears Say
No Reported Revenue (2025 & TTM)Having no reported commercial revenue means the company lacks an internal funding engine and remains fully development-stage. Over the medium term this raises execution risk: programs must be financed externally and clinical setbacks would materially impair the firm's ability to advance multiple programs.
Sustained Heavy Cash BurnPersistent negative operating and free cash flow at roughly -$23–25M annually indicates ongoing reliance on outside capital. This constrains multi-year trial execution, forces prioritization of programs and increases vulnerability to funding gaps that could delay milestones or force unfavorable financing.
Reliance On Equity Financing (ATM Program)An expanded at-the-market equity program signals dependence on dilutive equity to fund operations. Over time this raises dilution risk for existing holders, can pressure share-based compensation practices, and may limit strategic flexibility if market conditions prevent timely capital raises.
Tvardi Therapeutics News
TVRD FAQ
What was Tvardi Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Tvardi Therapeutics’s market cap?
Tvardi Therapeutics’s market cap is CHF15.91M.
When is Tvardi Therapeutics’s upcoming earnings report date?
Tvardi Therapeutics’s upcoming earnings report date is Aug 13, 2026 which is in 12 days.
How were Tvardi Therapeutics’s earnings last quarter?
Currently, no data Available
Is Tvardi Therapeutics overvalued?
According to Wall Street analysts Tvardi Therapeutics’s price is currently Undervalued.
Does Tvardi Therapeutics pay dividends?
Tvardi Therapeutics does not currently pay dividends.
What is Tvardi Therapeutics’s EPS estimate?
Tvardi Therapeutics’s EPS estimate is -0.56.
How many shares outstanding does Tvardi Therapeutics have?
Currently, no data Available
What happened to Tvardi Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tvardi Therapeutics?
Currently, no hedge funds are holding shares in CH:TVRD
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Tvardi Therapeutics
Tvardi Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of novel, oral, and small molecule therapies targeting signal transducer and activator of transcription 3 (STAT3) to treat inflammatory and proliferative diseases with significant unmet need in the United States. The company's lead product candidates include TTI-101, which is in Phase 1b/2 clinical development stage for fibrosis-driven diseases with an initial focus on idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC); and TTI-109, an oral, small molecule STAT3 inhibitor which is in Phase-1 clinical trial stage. Tvardi Therapeutics, Inc. was founded in 2017 and is based in Sugar Land, Texas.
TVRD Stock 12 Month Forecast
Average Price Target
―Plus Therapeutics
―
Cue Biopharma
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Adlai Nortye Ltd. Sponsored ADR
―